Synopsis of recent research by authors named "John R Butler"
- John R Butler's recent research focuses on developing therapeutic agents targeting specific proteins, such as the PRMT5 inhibitor AMG 193 for MTAP-deleted cancers and Na1.7 inhibitors for pain relief, highlighting the importance of synthetic lethality and selective pharmacological action in cancer and pain management.
- Findings from his studies demonstrate that AML 193 effectively induces DNA damage and cell cycle arrest in MTAP-deleted cancer cells, while also emphasizing the need for optimization of Na1.7 inhibitors to reduce off-target effects and enhance efficacy.
- Additionally, Butler has contributed to the synthesis of biologically significant natural products, including the enantioselective synthesis of compounds like kibdelone C, which exhibit potent cytotoxicity, showcasing his multi-faceted approach to both medicinal chemistry and synthetic methods.
